Detalles de la búsqueda
1.
Efficacy and Safety of Apremilast in Systemic- and Biologic-Naive Patients With Moderate Plaque Psoriasis: 52-Week Results of UNVEIL.
J Drugs Dermatol
; 17(2): 221-228, 2018 Feb 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-29462231
2.
Long-term safety and tolerability of apremilast in patients with psoriasis: Pooled safety analysis for ≥156 weeks from 2 phase 3, randomized, controlled trials (ESTEEM 1 and 2).
J Am Acad Dermatol
; 77(2): 310-317.e1, 2017 Aug.
Artículo
en Inglés
| MEDLINE | ID: mdl-28416342
3.
Evaluation of the Physician Global Assessment and Body Surface Area Composite Tool for Assessing Psoriasis Response to Apremilast Therapy: Results from ESTEEM 1 and ESTEEM 2.
J Drugs Dermatol
; 16(2): 147-153, 2017 Feb 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-28300857
4.
Efficacy and Safety of Apremilast in Patients With Moderate Plaque Psoriasis With Lower BSA: Week 16 Results from the UNVEIL Study.
J Drugs Dermatol
; 16(8): 801-808, 2017 Aug 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-28809995
5.
Apremilast, an oral phosphodiesterase-4 inhibitor, in the treatment of palmoplantar psoriasis: Results of a pooled analysis from phase II PSOR-005 and phase III Efficacy and Safety Trial Evaluating the Effects of Apremilast in Psoriasis (ESTEEM) clinical trials in patients with moderate to severe psoriasis.
J Am Acad Dermatol
; 75(1): 99-105, 2016 Jul.
Artículo
en Inglés
| MEDLINE | ID: mdl-27021239
6.
Apremilast, an oral phosphodiesterase 4 inhibitor, in patients with difficult-to-treat nail and scalp psoriasis: Results of 2 phase III randomized, controlled trials (ESTEEM 1 and ESTEEM 2).
J Am Acad Dermatol
; 74(1): 134-42, 2016 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-26549249
7.
Effects of Apremilast on Pruritus and Skin Discomfort/Pain Correlate With Improvements in Quality of Life in Patients With Moderate to Severe Plaque Psoriasis.
Acta Derm Venereol
; 96(4): 514-20, 2016 May.
Artículo
en Inglés
| MEDLINE | ID: mdl-26837052
8.
Assessing clinical response and defining minimal disease activity in plaque psoriasis with the Physician Global Assessment and body surface area (PGA × BSA) composite tool: An analysis of apremilast phase 3 ESTEEM data.
J Am Acad Dermatol
; 77(6): 1178-1180, 2017 Dec.
Artículo
en Inglés
| MEDLINE | ID: mdl-29132853
9.
Reduced dose and duration of peginterferon alfa-2b and weight-based ribavirin in patients with genotype 2 and 3 chronic hepatitis C.
J Hepatol
; 55(3): 554-563, 2011 Sep.
Artículo
en Inglés
| MEDLINE | ID: mdl-21237227
Resultados
1 -
9
de 9
1
Próxima >
>>